Brickell Bio Invested 2019 | Exited 2019

In July 2019, Brickell successfully completed a merger with Vical Incorporated (Nasdaq:VICL) in an all-stock transaction, creating a liquidity event for VisionTech Angels investors. The combined company operates as Brickell Biotech, Inc. and trades on the Nasdaq Capital Market. Brickell Bio is a clinical stage pharmaceutical company focused on developing innovative and differentiated therapeutics for treating skin diseases. Brickell’s lead pipeline asset, sofpironium bromide, is a pivotal Phase 3-ready topical soft anticholinergic intended for axillary hyperhidrosis (chronic excessive perspiration). The company’s pipeline also includes potential novel therapeutics for cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases.